Cargando…

Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA

OBJECTIVE: Poor medication adherence remains highly prevalent and adversely affects health outcomes. Patients frequently describe properties of the pills themselves, like size and shape, as barriers, but this has not been evaluated objectively. We sought to determine the extent to which oral medicat...

Descripción completa

Detalles Bibliográficos
Autores principales: Lauffenburger, Julie C, Tesfaye, Helen, Solomon, Daniel H, Antman, Elliott M, Glynn, Robert J, Lee, Su Been, Tong, Angela, Choudhry, Niteesh K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649612/
https://www.ncbi.nlm.nih.gov/pubmed/37949625
http://dx.doi.org/10.1136/bmjopen-2023-075840
_version_ 1785135592388952064
author Lauffenburger, Julie C
Tesfaye, Helen
Solomon, Daniel H
Antman, Elliott M
Glynn, Robert J
Lee, Su Been
Tong, Angela
Choudhry, Niteesh K
author_facet Lauffenburger, Julie C
Tesfaye, Helen
Solomon, Daniel H
Antman, Elliott M
Glynn, Robert J
Lee, Su Been
Tong, Angela
Choudhry, Niteesh K
author_sort Lauffenburger, Julie C
collection PubMed
description OBJECTIVE: Poor medication adherence remains highly prevalent and adversely affects health outcomes. Patients frequently describe properties of the pills themselves, like size and shape, as barriers, but this has not been evaluated objectively. We sought to determine the extent to which oral medication properties thought to be influential translate into lower objectively-measured adherence. DESIGN: Retrospective cohort study. SETTING: US nationwide commercial claims database, 2016–2019. PARTICIPANTS: Among patients initiating first-line hypertension, diabetes or hyperlipidaemia treatment based on clinical guidelines, we measured pill size, shape, colour and flavouring, number of pills/day and fixed-dose combination status as properties. OUTCOME MEASURES: Outcomes included discontinuation after the first fill (ie, never filling again over a minimum of 1-year follow-up) and long-term non-adherence (1-year proportion of days covered <0.80). We estimated associations between each property and outcomes, by therapeutic class (eg, statins), with multivariable logistic regression. RESULTS: Across 604 323 patients, 14.6% discontinued after filling once (ie, were non-persistent), and 54.0% were non-adherent over 1-year follow-up. Large pill size was associated with non-adherence, except for thiazides (eg, metformin adjusted OR (aOR): 1.12, 95% CI: 1.06 to 1.18). Greater pill burden was associated with a higher risk of non-adherence across all classes (eg, metformin aOR: 1.58, 95% CI: 1.53 to 1.64 for two pills/day). Taking less than one pill/day was also associated with higher risk of non-adherence and non-persistence (eg, non-persistence statin aOR: 1.29, 95% CI: 1.20 to 1.38). Pill shape, colour, flavouring and combination status were associated with mixed effects across classes. CONCLUSIONS: Pill burden and pill size are key properties affecting adherence for almost all classes; others, like size and combination, could modestly affect medication adherence. Clinical interventions could screen patients for potential intolerance to medication and potentially implement more convenient dosing schedules.
format Online
Article
Text
id pubmed-10649612
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-106496122023-11-10 Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA Lauffenburger, Julie C Tesfaye, Helen Solomon, Daniel H Antman, Elliott M Glynn, Robert J Lee, Su Been Tong, Angela Choudhry, Niteesh K BMJ Open Public Health OBJECTIVE: Poor medication adherence remains highly prevalent and adversely affects health outcomes. Patients frequently describe properties of the pills themselves, like size and shape, as barriers, but this has not been evaluated objectively. We sought to determine the extent to which oral medication properties thought to be influential translate into lower objectively-measured adherence. DESIGN: Retrospective cohort study. SETTING: US nationwide commercial claims database, 2016–2019. PARTICIPANTS: Among patients initiating first-line hypertension, diabetes or hyperlipidaemia treatment based on clinical guidelines, we measured pill size, shape, colour and flavouring, number of pills/day and fixed-dose combination status as properties. OUTCOME MEASURES: Outcomes included discontinuation after the first fill (ie, never filling again over a minimum of 1-year follow-up) and long-term non-adherence (1-year proportion of days covered <0.80). We estimated associations between each property and outcomes, by therapeutic class (eg, statins), with multivariable logistic regression. RESULTS: Across 604 323 patients, 14.6% discontinued after filling once (ie, were non-persistent), and 54.0% were non-adherent over 1-year follow-up. Large pill size was associated with non-adherence, except for thiazides (eg, metformin adjusted OR (aOR): 1.12, 95% CI: 1.06 to 1.18). Greater pill burden was associated with a higher risk of non-adherence across all classes (eg, metformin aOR: 1.58, 95% CI: 1.53 to 1.64 for two pills/day). Taking less than one pill/day was also associated with higher risk of non-adherence and non-persistence (eg, non-persistence statin aOR: 1.29, 95% CI: 1.20 to 1.38). Pill shape, colour, flavouring and combination status were associated with mixed effects across classes. CONCLUSIONS: Pill burden and pill size are key properties affecting adherence for almost all classes; others, like size and combination, could modestly affect medication adherence. Clinical interventions could screen patients for potential intolerance to medication and potentially implement more convenient dosing schedules. BMJ Publishing Group 2023-11-10 /pmc/articles/PMC10649612/ /pubmed/37949625 http://dx.doi.org/10.1136/bmjopen-2023-075840 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Public Health
Lauffenburger, Julie C
Tesfaye, Helen
Solomon, Daniel H
Antman, Elliott M
Glynn, Robert J
Lee, Su Been
Tong, Angela
Choudhry, Niteesh K
Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA
title Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA
title_full Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA
title_fullStr Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA
title_full_unstemmed Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA
title_short Investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the USA
title_sort investigating the ability to adhere to cardiometabolic medications with different properties: a retrospective cohort study of >500 000 patients in the usa
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649612/
https://www.ncbi.nlm.nih.gov/pubmed/37949625
http://dx.doi.org/10.1136/bmjopen-2023-075840
work_keys_str_mv AT lauffenburgerjuliec investigatingtheabilitytoadheretocardiometabolicmedicationswithdifferentpropertiesaretrospectivecohortstudyof500000patientsintheusa
AT tesfayehelen investigatingtheabilitytoadheretocardiometabolicmedicationswithdifferentpropertiesaretrospectivecohortstudyof500000patientsintheusa
AT solomondanielh investigatingtheabilitytoadheretocardiometabolicmedicationswithdifferentpropertiesaretrospectivecohortstudyof500000patientsintheusa
AT antmanelliottm investigatingtheabilitytoadheretocardiometabolicmedicationswithdifferentpropertiesaretrospectivecohortstudyof500000patientsintheusa
AT glynnrobertj investigatingtheabilitytoadheretocardiometabolicmedicationswithdifferentpropertiesaretrospectivecohortstudyof500000patientsintheusa
AT leesubeen investigatingtheabilitytoadheretocardiometabolicmedicationswithdifferentpropertiesaretrospectivecohortstudyof500000patientsintheusa
AT tongangela investigatingtheabilitytoadheretocardiometabolicmedicationswithdifferentpropertiesaretrospectivecohortstudyof500000patientsintheusa
AT choudhryniteeshk investigatingtheabilitytoadheretocardiometabolicmedicationswithdifferentpropertiesaretrospectivecohortstudyof500000patientsintheusa